ReviewBMJ oncology2025

Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective.

Alberto A Gabizon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.